Background and Aims
Having a body mass index above or equal to 30 kg/m2 in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.
This study evaluated impact of obesity on outcome as well as interferon and ribavirin concentrations following standard-of-care fixed dosing with peginterferon-α2a 180 µg once weekly and ribavirin 800 mg daily among 303 HCV genotype 2/3-infected patients enrolled in the per-protocol analysis of a recently completed phase III trial (NORDynamIC).
Patients with BMI ≥30 kg/m2 showed poorer outcome following 24 weeks of therapy (SVR 62% vs. 89% for BMI ≥30 vs. <30; P = 0.006) along with significantly higher steatosis grade (P = 0.002), HOMA-IR (P<0.0001), triglyceride levels (P = 0.0002), and baseline viral load (P = 0.028). Obesity was also significantly associated with lower plasma interferon concentrations on days 3, 7, and 29 (P = 0.02, P = 0.0017, and P<0.0001, respectively) and lower plasma ribavirin concentrations day 29 (P = 0.025), and lower concentration of interferon in turn was associated with a poorer first phase reduction in HCV RNA (P<0.0001). In multivariate analysis, ribavirin concentrations week 12, interferon concentrations day 29, and baseline HCV RNA levels were independent predictors of achieving SVR among patients treated for 24 weeks (n = 140).
Reduced bioavailability of interferon and ribavirin along with higher baseline viral load are dominant risk factors for treatment failure in obese patients with chronic hepatitis C.
Citation: Alsiö Å, Rembeck K, Askarieh G, Christensen PB, Färkkilä M, Langeland N, et al. (2012) Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. PLoS ONE 7(5): e37521. doi:10.1371/journal.pone.0037521
Editor: Maureen J. Donlin, Saint Louis University, United States of America
Received: February 10, 2012; Accepted: April 20, 2012; Published: May 24, 2012
Copyright: © 2012 Alsiö et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Swedish Society of Medicine, The Swedish Medical Research Council, Cancerfonden, The Torsten and Ragnar Söderberg Foundation, The Swedish Society of Microbiology, and ALF (Avtal om Läkarutbildning och Forskning) Funds at the Sahlgrenska University Hospital. Unrestricted grants from Roche affiliates in the Nordic region also supported this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have read the journal's policy and have the following conflicts: Unrestricted grants from Roche affiliates in the Nordic region also supported this study. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Hepatitis C virus (HCV) is the foremost cause of parenterally transmitted hepatitis , , and chronic infection is associated with liver fibrosis, cirrhosis, and hepatocellular carcinoma , . Treatment with pegylated interferon-α and ribavirin yields sustained viral response (SVR) rates of 50–80% , , , with higher SVR rates seen in patients infected with HCV of genotypes 2 and 3.
Thirty percent of American adults are obese, i.e. have a body mass index (BMI) above or equal to 30 kg/m2 . High BMI in conjunction with HCV is associated with steatosis in HCV genotype non-3 , increased fibrosis progression , and non-responsiveness to antiviral treatment , . Details regarding the mechanisms whereby obesity reduces the efficacy of combination therapy, however, remain unclear. It has been hypothesized that high BMI induces: (i) the metabolic syndrome leading to insulin resistance, hepatic steatosis, and higher baseline viral load , (ii) altered cytokine signaling as manifested by elevated levels of leptin, adiponectin, and resistin , and (iii) reduced bioavailability of interferon-α . The aim of this study was to identify independent risk factors for treatment failure among obese patients who participated in a phase III trial (NORDynamIC; n = 303) using standard dosing of peginterferon-α2a and ribavirin in chronic HCV genotype 2 and 3 infection.
Materials and Methods
The NORDynamIC trial
Three hundred and eighty-two treatment naïve patients with HCV genotype 2/3 infection were randomized at baseline to either 12 or 24 weeks of combination treatment with peginterferon-α2a 180 µg once weekly and ribavirin 800 mg daily. The first dose of study medication was administered under the supervision of a study nurse, and a patient diary monitored subsequent dosing. Because plasma concentrations of peginterferon-α2a and ribavirin were analyzed and in order to minimize the impact of adherence, patients constituting the per-protocol population (i.e. having received at least 80% of the target dose of peginterferon-α2a as well as at least 80% of the target dose of ribavirin for at least 80% of the target treatment duration) were included. Of 303 eligible patients, a body mass index could be calculated for 300, and these latter patients were included in the present study (baseline characteristics in Table 1). Further details regarding this trial are provided elsewhere .
Classification of response
Patients were classified as achieving SVR if plasma HCV RNA was undetectable (i.e. <15 IU/mL) 24 weeks after completion of therapy, as having relapsed if plasma HCV RNA was undetectable at end-of-treatment but detectable 24 weeks after completion of therapy, and as being non-responders if plasma HCV RNA was detectable at end-of-treatment. Patients were classified as having a rapid virological response (RVR) if HCV RNA was undetectable day 29 and a complete early virological response (cEVR) if HCV RNA was undetectable week 12.
Plasma was obtained using PPT-tubes and HCV-RNA was determined by RT-PCR of plasma using Cobas AmpliPrep/COBAS TaqMan HCV Test (Roche Diagnostics, Branchburg, NJ), which quantifies HCV-RNA with a limit of detection of ≤15 IU/mL. HCV-RNA quantification was performed on days 0, 3, 7, 8, 29, week 8, week 12, week 24 (for those receiving 24 weeks of therapy), and 24 weeks after completion of therapy. All samples were frozen (−70°C), and subsequently analyzed at the central laboratory.
Homeostatic model assessment-insulin resistance (HOMA-IR)
Baseline fasting glucose (mmol/L) was measured locally whereas fasting serum insulin (mU/L, Architect Insulin, Abbott, Abbott Park, IL) was analyzed on frozen samples at the central laboratory. HOMA-IR was calculated using the formula: (Glucose×Insulin)/22.5 . It should be noted that a standardized reference range is lacking for HOMA-IR .
Interferon α2a drug concentration
Plasma concentration of interferon-α2a was measured at day 3, 7 (i.e. immediately before the second dose of peginterferon-α2a) and 29. All samples were collected using PPT-tubes, frozen (−70°C), and subsequently analyzed at a central laboratory. Quantification was performed using 20 µl plasma (diluted 1:5) on a solid-phase ELISA using high absorbant plates coated with interferon alfa antibody (AMS Biotechnology Ltd., Oxon, UK). The detection limit of the assay was 400 pg/mL.
Plasma samples for ribavirin drug concentration measurement were drawn immediately before the morning dose of ribavirin at day 29 (week 4) and at week 12, i.e. trough concentrations. Plasma ribavirin concentrations were measured by use of solid phase extraction and high-performance liquid chromatography (HPLC; Merck-Hitachi, Tokyo, Japan) followed by UV-detection (wavelength 215 nm).
Liver biopsies were obtained from all patients within 24 months prior to study entry. The evaluation was performed in a blinded fashion by two independent observers according to the Ishak protocol . In addition, steatosis was graded as follows: absent = 0, less than 30% of hepatocytes involved = 1, 30–70% of hepatocytes involved = 2, and more than 70% of hepatocytes involved = 3 .
Wilcoxon-Mann-Whitney U-test, Kruskal-Wallis test, Chi squared (χ2) test, and Spearman's rank correlation coefficient (rs) test was utilized to evaluate relationships between variables. After univariate analyses, multivariate analyses were performed on the per-protocol patients treated for 24 weeks with all variables associated with the endpoint (P<0.1) being entered. The variables entered in the multivariate analyses were age, BMI, Ishak fibrosis stage, steatosis grade, HOMA score, peg-interferon concentrations on day 3, 7 and 29, ribavirin concentrations day 29 and week 12, and baseline HCV RNA level. All statistical analyses were performed using SPSS (version19.0) and StatView (version 5.0, SAS Institute Inc., Cary, NC, USA). All reported p-values are two-sided, and p-values<0.05 were considered significant.
Written informed consent was obtained from each participating patient. Ethics committees in each participating country approved the study (i.e. Regional Ethical Review Board, Gothenburg, Sweden (Regionala etikprövningsnämnden i Göteborg), Regional Committee for Ethics in Medical Research, Bergen, Norway (Regionaletisk komite for medisinsk og helsefaglig forskning i Bergen), The Scientific Ethical Committee for the Region of Middle Jylland, Viborg, Denmark (Den Videnskabsetiske Komité for Region Midtjylland), The Scientific Ethical Committee for the Region of South Denmark, Vejle, Denmark (Den Videnskabsetiske Komité for Region Syddanmark), and the Ethics Committee, Department of Medicine for the Hospital District of Helsinki and Uusimaa, Finland (Etiska kommittén för invärtesmedicin)). The study has been registered at the NIH trial registry (ClinicalTrials.gov Identifier: NCT00143000).
A strong association was noted between liver histopathology and body mass index (BMI) as well as HOMA-IR with patients having higher BMI also having higher HOMA-IR (rs = 0.31, P<0.0001), indicative of insulin resistance and more pronounced steatosis and fibrosis (Figure 1). Spearman's rank correlation coefficient (rs) test for correlation between BMI and HOMA-IR was 0.31 (P<0.0001). When grouping according to HCV genotype, the association between steatosis and BMI remained significant for both genotypes 2 and 3, as did the correlation between BMI and HOMA-IR for genotype 3. As expected, patients with BMI ≥30 kg/m2 also had significantly higher systolic and diastolic blood pressure as well as baseline triglycerides levels (mean 1.5 vs. 1.0 mmol/L BMI ≥30 vs. <30 kg/m2, P = 0.0002; Table 1) indicative of the metabolic syndrome. In contrast BMI was not associated with IL28B genotype.
Box plots displaying the 10th, 25th, 50th, 75th, and 90th percentiles of BMI among patients grouped by steatosis grade (A; n = 279) and fibrosis stage (B; n = 279), as well as HOMA-IR among patients grouped according to BMI (C; n = 268). P-values obtained using Kruskal-Wallis test.
Higher BMI was correlated with significantly lower concentrations of interferon as measured on days 3 (rs = −0.21, P = 0.0006), 7 (rs = −0.28, P<0.0001), and 29 (rs = −0.38, P<0.0001), (association dichotomized for BMI < or ≥30 kg/m2 demonstrated in Figure 2) as well as ribavirin day 29 (rs = −0.32, P<0.0001) and week 12 (rs = −0.37, P = 0.0002) (association dichotomized for BMI < or ≥30 kg/m2 demonstrated in Figure 3), and these correlations were significant for both HCV genotype 2 and 3. Because the first dose of study medication was administered under the supervision of a study nurse, the lower interferon concentrations noted on days 3 and 7 could not be attributed to poor patient compliance. Similarly subsequent dosing was monitored by a patient diary, and only patients having received at least 80% of the target dose of peginterferon-α2a and at least 80% of the target dose of ribavirin for at least 80% of the target treatment duration were included in the analysis. Thus lower adherence to therapy was unlikely to contribute to the lower concentrations of interferon and ribavirin measured on day 29, and ribavirin at week 12. It should be noted that women overall had approximately 10% higher ribavirin concentrations even when adjusting for weight as previously reported , and that this has previously been hypothesized to be secondary to a lower erythrocyte particle concentration noted among women thus allowing for less erythrocyte-trapping of ribavirin.
Box plots displaying the 10th, 25th, 50th, 75th, and 90th percentiles of the plasma concentrations of peginterferon (pg/mL) treatment day 3, 7, and 29 (A–C respectively). P-values obtained using Mann-Whitney U-test.
Box plots displaying the 10th, 25th, 50th, 75th, and 90th percentiles of the plasma concentrations of ribavirin (µg/mL) treatment day 29 and week 12 (A and B respectively). P-values obtained using Mann-Whitney U-test.
Interferon concentrations at all three time-points sampled were significantly associated with the first phase decline in HCV RNA (Figure 4) for both HCV genotypes 2 and 3, but not with the second phase (rs = −0.05 and P = 0.4, rs = −0.022 and P = 0.7, and rs = 0.005 and P = 0.9 for interferon concentrations on days 3, 7, and 29 respectively); and this association between interferon concentrations and the first phase decline was independent of IL28B genotype. In contrast, ribavirin concentrations were not associated with either the first (rs = 0.018 and P = 0.8 and rs = −0.018 and P = 0.8 for ribavirin concentrations on day 29 and week 12 respectively) or second phase reduction of HCV RNA (rs = 0.018 and P = 0.8 and rs = 0.042 and P = 0.5 for ribavirin concentrations on day 29 and week 12 respectively).
Correlation between the plasma concentration of peginterferon (pg/mL) treatment day 3 and decline in HCV RNA (log10 IU/mL) between baseline and treatment day 3 of combination therapy evaluated by use of Spearman's rank correlation coefficient rs test.
Somewhat surprisingly higher BMI was correlated with higher baseline viral load (rs = 0.12, P = 0.038), and this correlation became more pronounced while on treatment as exemplified by treatment day 3 (rs = 0.18, P = 0.002), day 7 (rs = 0.15, P = 0.01), day 8 (rs = 0.20, P = 0.0006), day 29 (rs = 0.33, P<0.0001), week 8 (rs = 0.45, P<0.0001), and week 12 (rs = 0.49, P<0.0001). Similarly a non-significant trend towards a smaller first phase decline in HCV RNA as measured by the reduction from day 0 to 3 (mean 1.66 vs. 1.91 log10 IU/mL BMI ≥30 vs. <30 kg/m2) and second phase as measured by the reduction from day 8 to 29 (mean 0.79 vs. 0.83 log10 IU/mL per week BMI ≥30 vs. <30 kg/m2). However, the association noted between higher BMI and higher HCV RNA levels day 29 was not reflected by the proportion of patients achieving undetectable HCV RNA, i.e. RVR (20% vs. 18%, BMI ≥30 vs. <30 kg/m2). In contrast, obese patients were less likely to achieve undetectable HCV RNA week 12 (i.e. cEVR; Figure 5).
Histogram displaying the proportion achieving cEVR, SVR, relapse or non-response among patients treated for 24 weeks included in the per-protocol analysis grouped according to BMI. P-value obtained using Chi-squared test.
In addition to the effect on viral kinetics, BMI profoundly affected SVR especially among patients treated for the standard 24 weeks of treatment duration (Figure 5) with only 62% of patients with BMI ≥30 kg/m2 achieving SVR as compared to 89% among those with BMI <30 kg/m2 (P = 0.006). This decrease in SVR was mirrored by increased rates of relapse and non-response for both HCV genotypes 2 and 3. In univariate analysis of the population treated for 24 weeks, both peg-interferon and ribavirin concentration day 29 where significantly associated with SVR (P = 0.01), and in a multivariate analysis, ribavirin concentrations week 12, peg-interferon concentrations day 29, and baseline HCV RNA levels were independent predictors of achieving SVR (Table 2). Among patients treated for 12 weeks, those achieving SVR had significantly lower BMI than those that did not (mean 25.5 vs. 27.2 kg/m2; P = 0.02).
In spite of the pending introduction of direct antiviral agents (DAA) in routine clinical practice for HCV genotype 1, few of the currently available DAAs are active against genotype 2 or 3. Thus interferon-α and ribavirin are likely to retain pivotal roles in the management of chronic HCV genotype 2/3 infection, and a fixed dose of 800 mg/day ribavirin in conjunction with fixed 180 µg dosing of peginterferon-α2a  or weight-adjusted dosing of peginterferon-α2b  currently is the standard of care for these viral genotypes. In this setting, the main finding in the present study was that higher BMI was associated with significantly lower concentrations of ribavirin and interferon as well as poorer outcome following fixed dosing of ribavirin and peginterferon-α2a, that lower plasma concentrations of interferon were associated with a poorer first phase reduction in HCV RNA, and that both ribavirin and interferon concentrations along with baseline viral load were independent predictors of SVR.
The lower bioavailability of peginterferon noted in our study corroborates the findings reported by Lam et al. (among 11 HCV infected patients, 6 obese and 5 non-obese) who reported a non-significant trend towards lower interferon concentrations and higher baseline viral load following a single dose of 10 mIU of unpegylated interferon-α2b without the addition of ribavirin among obese patients. Interestingly in contrast to the present study, no difference in the first phase decline in HCV RNA was noted though the sample size was small .
The finding in the present study that patients with BMI ≥30 kg/m2 had significantly lower concentrations of ribavirin following fixed dosing of 800 mg ribavirin/day is not surprising, and may substantiate the report by Pattullo et al. that weight based dosing of ribavirin may negate the influence of BMI and weight on outcome . However, this latter study had only a limited number of patients infected with genotypes 2 (n = 22) or 3 (n = 31), and a substantial proportion of patients received weight based dosing of peginterferon-α2b. Fried et al. noted that among difficult-to-cure (i.e. body weight >85 kg and viral load >800,000 IU/mL) HCV genotype 1 infected patients higher fixed doses of both ribavirin (1600 mg daily) and peginterferon-α2a (270 µg/week) improved viral kinetics and SVR rates as compared to lower doses of ribavirin (1200 mg daily) and peginterferon-α2a (180 µg/week) . This is in contrast to the PROGRESS study where no benefit was noted from giving 1400/1600 mg ribavirin daily as compared to 1200 mg in an intention-to-treat analysis among difficult-to-treat (i.e. body weight ≥85 kg and viral load ≥400,000 IU/mL) HCV genotype 1 infected patients . It should be noted, however, that 42% of these patients had a BMI below 30 kg/m2, and no subset analysis restricted to patients with BMI ≥30 kg/m2 has yet been reported. Additionally in a per-protocol analysis restricted to patients with at least 80% exposure to the planned ribavirin dose, numerically higher SVR rates were obtained with intensified regimens suggesting that such strategies may be successful if tolerated .
Similarly it may be hypothesized that patients with BMI ≥30 kg/m2 may benefit from increased dosing of interferon, which is substantiated by the abovementioned study by Fried et al. . However, in the PROGRESS study no significant differences in SVR were noted in patients weighing ≥85 kg receiving a 12-week induction regime of 360 µg peginterferon-α2a weekly as compared to standard dosing in an intention-to-treat analysis . However, when the analysis was restricted to patients tolerating at least 80% of the planned interferon dosing, numerically higher SVR rates were achieved with intensified regimens reiterating the importance of adherence . Additionally the potential benefit of exposure to higher doses of interferon beyond 12 weeks of therapy was not investigated in this latter study. Similarly, in the IDEAL study, no significant difference in SVR was noted among patients with higher weight regardless whether they received weight based dosing of peginterferon-α2b or a fixed 180 µg dosing of peginterferon-α2a although a non-significant trend towards slightly higher SVR rates was noted in patients weighing between 105 and 125 kg who received weight based dosing of interferon (44.9%, 42.1%, and 38.9% for peginterferon-α2b 1.0 and 1.5 µg/kg body weight and 180 µg peginterferon-α2a respectively) . However, it should be noted that in this weight class patients treated with peginterferon-α2b received 1400 mg ribavirin daily as opposed to 1200 mg daily for patients treated with peginterferon-α2a, and thus lower ribavirin dosing may have contributed to the lower numerical SVR rates noted following fixed interferon dosing.
In addition to differences in bioavailability of interferon and ribavirin, we also noted that patients with higher BMI had higher baseline viral load, more pronounced steatosis, in addition to features of the metabolic syndrome as previously reported, e.g. higher systolic and diastolic blood pressure, higher HOMA-IR, and higher baseline triglyceride levels. Although weight reduction among obese HCV patients is known to normalize many aspects of the metabolic syndrome as well as liver histology ,  and thus is likely to have a beneficial impact on combination therapy for HCV, this cannot be addressed in the present study. Similarly whether increased treatment duration beyond 24 weeks for patients with BMI ≥30 kg/m2 would improve outcome is outside the scope of this study. Since replication, assembly and release of HCV occurs in close proximity to intracellular lipid droplets , the finding of a higher baseline viral load among obese patients, hypothetically, may be secondary to the elevated pre-treatment plasma triglyceride levels or to more advanced steatosis.
In conclusion, higher BMI is associated with lower bioavailability of both peginterferon and ribavirin, which subsequently along with higher baseline viral load are dominant risk factors for treatment failure in obese patients with chronic HCV genotypes 2 and 3 infection.
We thank Anne-Sofie Tylö, Marie-Louise Landelius, Jenny Hendel, and Ulla Gingsjö for expert technical assistance.
Conceived and designed the experiments: ÅA KR PC ML. Performed the experiments: ÅA PC ML JW. Analyzed the data: ML ÅA KR GA SN JW. Contributed reagents/materials/analysis tools: PC MF NL MRB CP KM BH GN. Wrote the paper: ML ÅA KR KH.
- 1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359–362.
- 2. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, et al. (1989) Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321: 1494–1500.
- 3. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, et al. (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87: 6547–6549.
- 4. Lagging LM, Westin J, Svensson E, Aires N, Dhillon AP, et al. (2002) Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 22: 136–144.
- 5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.
- 6. Hadziyannis SJ, Sette H , Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355.
- 7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965.
- 8. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, et al. (2004) Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 291: 2847–2850.
- 9. Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, et al. (2007) Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 14: 29–35.
- 10. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J (2002) Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97: 2408–2414.
- 11. Bressler BL, Guindi M, Tomlinson G, Heathcote J (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38: 639–644.
- 12. Charlton MR, Pockros PJ, Harrison SA (2006) Impact of obesity on treatment of chronic hepatitis C. Hepatology 43: 1177–1186.
- 13. Harrison SA (2006) Correlation between insulin resistance and hepatitis C viral load. Hepatology 43: 1168; author reply 1168–1169:
- 14. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, et al. (2004) Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 12: 962–971.
- 15. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, et al. (1997) Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 42: 178–185.
- 16. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, et al. (2008) Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47: 1837–1845.
- 17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.
- 18. Qu HQ, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB (2011) The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. PloS one 6: e21041.
- 19. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696–699.
- 20. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R (2002) Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37: 837–842.
- 21. Pedersen C, Alsio A, Lagging M, Langeland N, Farkkila M, et al. (2011) Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. J Viral Hepat 18: 245–251.
- 22. Jacobson IM, Brown RS , Freilich B, Afdhal N, Kwo PY, et al. (2007) Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46: 971–981.
- 23. Pattullo V, Ravindran NC, Mazzulli T, Wong DK, Heathcote EJ (2010) Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C. J Viral Hepat 17: 834–838.
- 24. Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, et al. (2008) Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 48: 1033–1043.
- 25. Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, et al. (2010) Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 139: 1972–1983.
- 26. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, et al. (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580–593.
- 27. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, et al. (2004) Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53: 413–419.
- 28. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, et al. (2002) Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51: 89–94.
- 29. McLauchlan J (2009) Lipid droplets and hepatitis C virus infection. Biochim Biophys Acta 1791: 552–559.